News|Articles|November 16, 2026

Tumor Treating Fields Improve Pain and Quality of Life in Pancreatic Cancer

Author(s)Matt Flowers
Fact checked by: Sabrina Serani
Listen
0:00 / 0:00

Key Takeaways

  • PANOVA-3 randomized 571 patients to TTFields plus gemcitabine/nab-paclitaxel versus chemotherapy alone, with QOL captured by EORTC QLQ-C30 and QLQ-PAN26 over 26 months.
  • Global health status deterioration-free survival favored TTFields (7.1 vs 5.7 months; HR 0.77), while most functioning domains were similar, suggesting symptom relief without broad functional divergence.
SHOW MORE

Findings from the phase 3 PANOVA-3 trial showed that adding tumor treating fields to gemcitabine and nab-paclitaxel prolonged time to quality-of-life deterioration and improved pain outcomes in unresectable, locally advanced pancreatic cancer.

The addition of tumor treating fields (TTFields) therapy to gemcitabine and nab-paclitaxel improved pain outcomes and prolonged quality of life (QOL) deterioration-free survival among patients with unresectable, locally advanced pancreatic adenocarcinoma, according to a prespecified secondary analysis of the phase 3 PANOVA-3 trial (NCT03377491) published in JAMA Network Open.¹

The findings provide additional evidence supporting TTFields therapy as a first-line treatment approach in this patient population, building on previously reported overall survival (OS) benefits from the randomized trial.

PANOVA-3 Demonstrated Improvements in QOL Outcomes

PANOVA-3 was a global, open-label, multicenter, randomized phase 3 trial evaluating TTFields therapy at a frequency of 150 kHz in combination with gemcitabine and nab-paclitaxel vs chemotherapy alone. A total of 571 patients with previously untreated, unresectable, locally advanced pancreatic adenocarcinoma were randomized 1:1 to receive either treatment approach.

The secondary analysis evaluated patient-reported QOL using the EORTC QLQ-C30 and its 26-item pancreatic cancer module (QLQ-PAN26). These instruments assessed global health status, physical and functional well-being, digestive symptoms, general pain, and pancreatic cancer–specific pain.

Among 562 patients who completed the baseline EORTC QLQ-C30 questionnaire, global health status remained stable throughout the 26-month follow-up period in both treatment groups. However, patients receiving TTFields therapy with gemcitabine and nab-paclitaxel experienced improvements in digestive symptoms, general pain, and pancreatic pain beginning 2 months after treatment initiation, with these improvements maintained throughout follow-up.

In contrast, pancreatic pain deteriorated between months 18 and 26 among patients receiving chemotherapy alone.

TTFields therapy was also associated with longer deterioration-free survival for global health status compared with chemotherapy alone. Median deterioration-free survival was 7.1 months (95% CI, 3.5-14.8) vs 5.7 months (95% CI, 2.3-11.5), respectively (HR, 0.77; 95% CI, 0.61-0.97; P = .02).

Not all functional outcomes differed between treatment groups. Deterioration-free survival for physical, role, emotional, cognitive, and social functioning was similar between the arms, although improvements were observed across several digestive symptom measures.

Pain Control and Delayed Opioid Use Further Support Findings

Additional analyses demonstrated improvements in both general and pancreatic cancer–specific pain outcomes. Median deterioration-free survival for general pain was 10.1 months (95% CI, 4.0-20.9) with TTFields therapy plus chemotherapy vs 7.4 months (95% CI, 3.5-14.5) with chemotherapy alone (HR, 0.70; 95% CI, 0.54-0.89; P = .003).

For pancreatic pain, median deterioration-free survival was 14.7 months (95% CI, 6.2-46.2) vs 10.2 months (95% CI, 5.6-18.2), respectively (HR, 0.69; 95% CI, 0.52-0.90; P = .006).¹

A post hoc analysis of pain medication use also showed that TTFields therapy was associated with delayed opioid use. In the modified intention-to-treat population, median time to opioid use was 9.3 months with TTFields therapy plus chemotherapy compared with 6.7 months with chemotherapy alone (HR, 0.72; 95% CI, 0.55-0.93; P = .01).

At 1 year after treatment initiation, 37.2% of patients receiving TTFields therapy plus chemotherapy had not used opioid pain medications compared with 29.5% of those receiving chemotherapy alone (P = .04). The authors noted that differences in the use of stronger and weaker opioids were not statistically significant.

"One of the most debilitating complications of pancreatic cancer is pain. For clinicians, management of pain is a priority because it not only affects our patients’ quality of life but it can reduce compliance with anticancer treatments, negatively impacting survival outcomes," Teresa Macarulla, MD, PhD, head of the Medical Oncology Department at Hospital Clínic Barcelona Comprehensive Cancer Centre, said in a news release.²

OS Benefits and Study Limitations Provide Additional Context

The QOL findings build on the primary PANOVA-3 results, which demonstrated a statistically significant OS improvement with TTFields therapy plus gemcitabine and nab-paclitaxel. Median OS was 16.2 months (95% CI, 15.0-18.0) compared with 14.2 months (95% CI, 12.8-15.4) with chemotherapy alone (HR, 0.82; 95% CI, 0.68-0.99; P = .039).³

The FDA approved TTFields therapy in combination with gemcitabine and nab-paclitaxel for adults with unresectable, locally advanced pancreatic cancer, providing a new treatment option for this patient population.

The combination also prolonged pain progression-free survival, with median outcomes of 15.2 months vs 9.1 months, respectively.

Regarding safety, TTFields therapy was generally well tolerated, with mild to moderate skin reactions representing the most common device-related adverse events. No new safety signals were identified in the trial.²

The investigators acknowledged limitations, including the open-label design and the absence of a sham device in the control arm, which could have influenced subjective patient-reported outcomes. Additionally, the analysis of pain medication use was post hoc and should be interpreted cautiously.¹

Overall, the findings suggest that adding TTFields therapy to gemcitabine and nab-paclitaxel may offer benefits beyond survival, particularly in maintaining QOL and delaying worsening pain for patients with unresectable, locally advanced pancreatic adenocarcinoma.

REFERENCES
1. Macarulla T, Picozzi V, Chandana SR, et al. Tumor treating fields and quality of life among patients with locally advanced pancreatic adenocarcinoma: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2026;9(11):e2641241. doi:10.1001/jamanetworkopen.2026.41241
2. JAMA Network Open publishes quality of life and pain outcomes data from phase 3 PANOVA-3 trial of Novocure's tumor treating fields for pancreatic cancer. News release. Novocure; November 13, 2026. Accessed November 16, 2026. https://tinyurl.com/mvbpysx9
3. Babiker HM, Picozzi V, Chandana SR, et al. Tumor treating fields with gemcitabine and nab-paclitaxel for locally advanced pancreatic adenocarcinoma: randomized, open-label, pivotal phase 3 PANOVA-3 study. J Clin Oncol. 2025;43(21):2350-2360. doi:10.1200/JCO-25-00746

Related to this article